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1. Introduction 
Over the last decade biomedical research has seen tremendous advancements in the field 
of genetics that enables unlimited access to >60 vertebrate genomes—including the human 
and mouse genomes, two of the most widely studied species in biomedical research. 
These advancements are largely due to rapid development of high throughput sequencing 
technologies such as next-generation sequencing (NGS) technologies that allow for more 
affordable and efficient sequencing compared to traditional Sanger technology. The 
availability of the entire human genome sequence has accelerated our efforts to gain 
insight into the genetics underlying human disease. Such efforts include Genome-Wide 
Association Studies (GWAS) — a widely used approach that examines the association 
between common genetic variants and specific human disease traits. GWAS has led to the 
successful identification of a large number of SNPs that are linked with chronic diseases 
ranging from Crohn’s disease, systemic lupus erythermatosus (SLE), type I diabetes 
(T1D), and many other common western world diseases(reviewed by Visscher et al.1). On 
the other hand, genetic deficiencies that cause severe disease—such as primary 
immunodeficiency diseases associated with a poor survival— represent mostly rare 
mutations within the human population2. Such patients can be found in pediatric clinics 
and more often than not, the genetic deficiencies underlying disease remain elusive. The 
availability of NGS, however, offers exciting new opportunities in that it enables the 
identification of all genome-wide variants in individual patients for limited costs. 
Nonetheless, both approaches are faced with a significant challenge to identify the causal 
variants. First of all, most GWAS identify loci that contain more than one SNP but more 
importantly, SNP maps are incomplete and require in depth probing of the identified 
genetic region (reviewed by Visscher et al.1). Thus the approach is generally not limited to 
a single SNP, but rather uncovers multiple gene candidates for a single locus and 
researchers are often left with the critical question to identify variant causality. This is 
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further complicated by the fact that GWAS is often used for the analysis of complex 
polygenic traits where gene variants need to exist in combination with one other to assert 
an effect. In the case of monogenic traits underlying severe disease phenotypes, linkage 
analysis is rarely an option, whereas whole genome sequencing likely results in the 
identification of numerous “unique” variants. The biological consequences of such 
variants would again need to be confirmed and candidate gene selections are guided by a 
priori knowledge of gene function. Thus the challenges have rather shifted from 
identifying genetic changes to understanding gene-function and identifying gene 
causality.  
Providing insight into the functional genome is not just limited to understanding gene or 
protein function, but also includes gene regulation and complex interactions with other 
genes within the context of cellular or organismal function. The mammalian genome is 
believed to consist of ~22,000 annotated genes—most of which have been poorly described. 
In addition, there is almost an unlimited number of phenotypes to be probed, making this 
an even more daunting task. Nonetheless, experimental models, including fruit fly and 
mouse models, have been extremely valuable in revealing unique insight into gene function. 
Typically, forward and reverse genetic approaches have been applied in parallel to uncover 
gene function. Reverse genetics begins with the creation of a genetic change and ends with 
the identification of a phenotype. This approach is hypothesis-based and assumes a specific 
gene function up front. On the other hand, forward (or classical) genetics proceeds from 
phenotype to the identification of a causal genetic change (SNP or mutation). This approach 
has led to important discoveries in the field of immunology most notably the identification 
of TLR4 as the sole LPS receptor3— a discovery recently awarded with the Nobel Prize. 
Until a few years ago, identification of such genetic variants required positional cloning. 
This was once considered an arcane art, requiring significant effort, time and financial 
resources. However, the current availability of the genome sequence for most inbred mouse 
strains has eliminated the need for contig construction and trivialized the identification of 
informative markers for high-resolution mapping and/or the identification of existing 
variants within an associated chromosomal region. Moreover, low cost high-throughput 
DNA sequencing has accelerated the process of finding unique mutations either introduced 
spontaneously or by following treatment with mutagens. The current limitation for forward 
genetics is rather the restricted number of strong monogenic phenotypes, something also 
referred to as the “phenotype gap”4. To overcome this limitation, germline mutagenesis— in 
which random mutations are introduced in spermatogonial stem cells— has proven to be an 
effective approach to expand the number of phenotypes.  
2. N-ethyl-N-nitrosourea mutagenesis  
In mice, a widely used mutagen to create and expand the number of phenotypes is the 
alkylating agent N-ethyl-N-nitrosourea (ENU). ENU is a powerful mutagen that according 
to our latest estimates can introduce more than 3 base-pair changes per million base-pairs of 
genomic DNA5. ENU introduces point mutations in spermatogonial stem cells, 
predominantly affecting A/T base pairs (44% A/T→T/A transversions and 38% A/T→G/C 
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transitions), whereas at the protein level, ENU primarily results in missense mutations (64% 
missense, 26% splicing errors and 10% nonsense mutations)6. With three bp changes per 
million bps and a total length of ~2,717 Mb for the mouse genome, one can calculate that 
each G1 male carries ~8,000 bp changes genome-wide. With the coding region being 1.3% of 
total genomic sequence and 76% of random bp changes creating a coding change, it follows 
that each G1 mouse carries about 80 coding changes genome-wide, according to our latest 
estimates. These exist in a heterozygous form and do not necessarily cause a phenotype. In 
our experience, the majority of ENU-induced mutations, behave as recessive traits or are 
codominant at best. The approach entails a weekly injection of ~90mg/kg ENU for 3 weeks 
that is followed by a brief period of sterility for up to 12 weeks. After the recovery period, 
each G0 male is bred to untreated, wild type C57BL/6 female mice to generate G1 offspring. 
These G1 animals are then either used for phenotypic screens or can be used to produce G2 
mice, which in turn are backcrossed to the G1 male to generate G3 offspring. While 
screening the G1 population for phenotypes is limited to the identification of dominant 
mutations, screening of G3 mice allows for the discovery of recessive mutations. Although 
the total number of base-pair changes in G3 mice will be reduced—each mouse will carry 
~11 coding changes in homozygous form—this has proven to be the more powerful 
approach to capture mice with phenotypes of interest and more importantly allows for the 
retrieval of lethal phenotypes.  
The rate-limiting step in ENU mutagenesis has long been the identification of causative 
mutations. Until recently, identified mutant lines were outcrossed to genetically different 
inbred strains and often the analyses of hundreds if not thousands of meiosis were needed 
to obtain a small enough critical region that could be sequenced. However, the availability 
of NGS has significantly facilitated the process of variant identification. Currently, targeted 
exon-enrichment—i.e. targeting exonic sequence within a critical region using sequence 
capture probes—, whole-exome and whole-genome sequencing are all proven strategies to 
effectively uncover mutations. The coverage of (targeted) genomic DNA is often 
exceptional, particularly for the exon-enrichment approach, where generally high quality 
sequence (minimal depth >10) for more than >98 % of the targeted region can be obtained5. 
Nonetheless, causality of the identified mutations remains a critical aspect of this approach 
and low resolution mapping (generally < 30 meioses) and/or genetic confirmation are still 
integral parts of the ENU mutagenesis approach. In addition, the availability of NGS also 
provides further opportunities for the phenotypic probing of ENU germline mutants. Often, 
phenotypes identified in ENU germline mice are lost or significantly influenced by modifier 
loci located on outcross strains carrying a high degree of genetic variation. For example, 
identification of genes required for optimal NK cell function has been difficult because of 
the large variation in NK cell ligands/receptors existing on different mouse backgrounds 
(Hoebe, unpublished results). By being able to analyze and sequence large genomic regions, 
fine mapping is superfluous and the exploration of subtle phenotypes can be traced 
following an outcross to strains with minimal genetic variation between the outcross and 
parent ENU strain. Ultimately, the genetic diversity should be just enough to allow low-
resolution linkage analysis—a prime example being the genetic diversity between C57BL/6J 
and C57BL/10J strains.  
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3. Unraveling lymphocyte immune function using ENU mutagenesis 
As referred to above, a critical aspect of ENU mutagenesis is the (biological) field of interest 
to be probed. ENU mutagenesis has been used to define the genetic footprint of a wide 
variety of phenotypes, including visible, behavioral, developmental and immunological 
phenotypes7. Nonetheless, its success is depending on: 1) the use of reliable screening assays 
with limited biological variation, 2) targeting large genomic footprints, and 3) probing a 
biological phenotype that is poorly defined. Our laboratory has used ENU mutagenesis to 
identify genes with non-redundant function in lymphocyte development, priming or 
effector function. Among the biological screens we apply is an in vivo cytotoxicity assay in 
which we test the ability of G3 mice to induce an antigen-specific CD8+ T cell response 
following immunization with irradiated cells containing antigen. In parallel, we test the 
ability of Natural Killer (NK) cells to recognize and eliminate “missing self” target cells in 
vivo—a process involving complex balancing interactions between activating and inhibitory 
NK cell receptors. Such screens are not just limited to identifying the presence/absence of 
NK cells and/or CD8+ T cells in vivo but challenges the host response to undergo NK cell 
recognition/killing, antigen uptake/ processing and presentation by Dendritic Cells (DCs), 
ultimately causing T cell priming, expansion and T cell cytolytic effector function. The in 
vivo immune responses assess the capacity of ENU mice to induce sterile inflammatory 
responses mediated by self-molecules that activate either NK cells and/or Toll-like receptor-
independent sensing pathways—the latter presumably activated by cell-death- or “danger-” 
associated molecular patterns (DAMPs). Importantly, the induction of type I or II IFNs are 
essential for the generation of antigen-specific T cell responses mediated via cell-death 
induced immune responses8. Whereas IFNs have been shown to promote the maturation of 
DCs and stimulate T cell priming, the underlying pathways inducing type I IFN following 
exposure of DCs to dying cells are less well defined. It is well established that host 
molecules such as DNA and/or RNA in apoptotic cells can cause sustained and systemic 
type I IFN production when they escape degradation in macrophages9-11. The pathways by 
which such nucleotide structures drive type I IFN production following administration of 
apoptotic cells remains still elusive to date. Thus, the in vivo cytotoxicity screen performed in 
our laboratory presents a large genetic footprint, not only comprising lymphocyte 
development but also targeting NK-, DC- and T cell biological function. As a result, we have 
identified a number of germline mutants that are either deficient in the IFN pathways, but 
also includes germline mutants that exhibit impaired lymphocyte survival, T cell activation 
and/or actin-polymerization. Here we will provide two examples how ENU germline 
mutants can provide new insight into gene function, immunological pathways and/or 
disease development.  
4. Gimap5 and loss of immunological tolerance driving auto-immune 
diseases 
Using N-ethyl-N-nitrosourea (ENU) germline mutagenesis, our laboratory previously 
identified Gimap5-deficient mice—designated sphinx—that exhibit reduced lymphocyte 
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survival and develop severe colitis around 10-12 weeks of age12. Specifically, these mice lack 
NK or CD8+ T cell populations in peripheral lymphoid organs, whereas relatively normal 
thymocyte development occurs, including the CD4+ T cell, CD8+ T cell, and Foxp3+ 
regulatory T cell lineages. Coarse mapping and sequencing of the critical region revealed a 
single G→T point mutation in Gimap5 to be the causal mutation. This mutation resulted in a 
G38C amino acid substitution in the predicted GTP-binding domain of Gimap5, 
destabilizing Gimap5 protein expression12. 
Gimap5 is part of the family of Gimap genes which are predominantly expressed in 
lymphocytes and regulate lymphocyte survival during development and homeostasis13. 
Gimap proteins contain a GTP-binding AIG1 homology domain, first identified in disease-
resistance genes in higher plants9, 10. More recent crystallographic studies showed that the 
Gimap proteins resemble a nucleotide coordination and dimerization mode previously 
observed for dynamin GTPase—a component essential for the scission and fusion of cellular 
vesicular compartments such as endosomes at the cell surface or the Golgi apparatus in the 
cytosol14. Members of the Gimap family appear to be localized to different subcellular 
compartments with Gimap5 reported to localize in lysosomes based on studies in human, 
mouse and rat lymphocytes15. Overall, the function of these proteins and their role in disease 
development remain poorly defined.  
Genetic aberrancies in Gimap5 have been strongly linked to reduced lymphocyte survival 
and homeostasis, but importantly have also been associated with autoimmune diseases. In 
humans, polyadenylation polymorphisms in GIMAP5—causing relative modest changes in 
GIMAP5 RNA expression—were associated with increased concentrations of IA2 auto-
antibodies in type 1 diabetes (T1D) patients and an increased risk of systemic lupus 
erythematosus (SLE)16, 17. Studies using biobreeding (BB) rats— carrying a mutation (lyp/lyp) 
in Gimap5— show marked lymphopenia and predisposition to the development of T1D18-22 
and intestinal inflammation23. Together these observations suggest that, beyond lymphocyte 
survival, Gimap5 is essential for maintaining immunological tolerance.  
Although in Gimap5sph/sph mice no auto-antibodies can be detected, males and females 
developed severe colitis around 8-12 weeks of age, which was dependent on the microbiome 
and is CD4+ T cell driven12. Interestingly, inflammatory bowel disease (IBD) such as Crohn’s 
disease, ulcerative colitis and indeterminate colitis24, 25 manifest generally in adolescence or 
adulthood and they behave as complex, polygenic diseases often sharing common risk 
factors with other autoimmune diseases26, 27. Previous work suggests that impaired 
lymphocyte survival and consequent lymphopenia may be linked to the loss of 
immunological tolerance. Specifically, CD4+ T cells in a lymphopenic environment can 
undergo thymic independent expansion in the periphery. This process—also referred to as 
lymphopenia-induced proliferation (LIP)—is accompanied by marked alterations in T cell 
phenotype and is linked to auto-immunity28-30. Most notably, CD4+ T cells more readily 
adopt an effector phenotype, including the ability to robustly produce cytokines and can 
drive the development of colitis31-33. Importantly, the absence of Treg cells is an important 
determinant of immune-mediated sequelae, including colitis that is induced by CD4+ T cells 
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undergoing LIP. Interestingly, studies in our laboratory show that in Gimap5sph/sph mice, the 
onset of colitis is preceded by a progressive reduction in circulating CD4+ T cells with 
remaining CD4+ T cells exhibiting a lymphopenia-induced proliferation (LIP) phenotype 
(CD44high and CD62low) with a large number of cells in S phase(12 and Figure 1). Moreover, 
CD4+ T cells derived from Gimap5sph/sph spleen or mesenteric lymph nodes (MLNs) exhibit a 
higher capacity to produce cytokines, i.e. IFNγ and/or IL-17A following activation of the T 
cell receptor.  
 
Figure 1. Schematic representation of the events causing colitis in Gimap5-deficient mice. Loss of 
Gimap5 leads to reduced survival of lymphocytes including CD4+ T cells (1). During lymphopenia, 
CD4+ T cells undergo LIP exemplified by increased surface expression of CD44 and reduced levels of 
CD62L (2). Concomitantly, CD4+ T cells exhibit loss of full-length FoxO1, FoxO3 and FoxO4 expression, 
affecting both immunosuppressive function or Treg cells and the induction of Treg cells in the 
mesenteric lymph nodes (3). Together these events promote Th17 differentiation and activation of CD4+ 
T cells in the gut causing inflammation and infiltration of macrophages / neutrophils that further 
amplify intestinal inflammation (4). 
Given the important role of regulatory T cells in immune-mediated sequelae induced by 
CD4+ T cells undergoing LIP, our laboratory assessed whether the colitis was driven by 
abnormalities in regulatory T cell development or function. Although relatively normal 
numbers of Foxp3+ Treg cells are found in 3-week-old mice, a loss of Treg cell numbers is 
observed by 6 weeks of age particularly in the MLNs34. In addition, regulatory T cells in 
Gimap5sph/sph mice show a progressive loss of suppressive function. Specifically, whereas Treg 
cells from 4-week-old Gimap5sph/sph mice show a slight, but significant reduction in their 
ability to suppress CD8+ T cell proliferation in vitro, Treg cells isolated from 6-week-old 
Gimap5sph/sph mice are incapable of suppressing CD8+ T cell proliferation entirely, thus 
indicating that a progressive impairment in Treg cell survival and function may underlie the 
colitis development in Gimap5sph/sph mice. Indeed, colitis can be prevented entirely by 
injecting wildtype regulatory T cells in 4-week-old Gimap5sph/sph mice.  
Interestingly, the T cell phenotypes in Gimap5sph/sph mice show striking similarities with those 
seen in mice deficient in the family of Forkheadbox group O (Foxo) transcription factors. 
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The family of Foxo transcription factors contain 4 members of which three (Foxo1, Foxo3 
and Foxo4) have overlapping patterns of expression and transcriptional activities35-37. They 
play an essential role in the quiescence and survival of CD4+ T cells. Foxo1 expression is 
critical for maintaining naïve T cell quiescence38-40. In addition, Foxo1, 3 expression has been 
reported to be essential for Treg cell development and function41, 42. Specifically, Foxo 
transcription factors serve a role as coactivators downstream of the TGFβ signaling pathway 
by interacting with SMAD proteins43, 44, and directly regulate the induction of a number of 
Treg cell associated genes, including Foxp3, CTLA-4 and CD2541, 42. Indeed immunoblot 
analysis of CD4+ T (including Treg cells) from Gimap5sph/sph mice at various ages, revealed a 
progressive loss of full-length Foxo1, -3a and -4 proteins, with normal levels at 3 weeks of 
age, but a complete loss of Foxo-expression in CD4+ T cells from 6-10 week-old Gimap5sph/sph 
mice34. The regulation of Foxo3 and Foxo4 protein expression appears to occur at the post-
transcriptional level, although the exact mechanism underlying the loss of Foxo-expression 
remains to be determined. The progressive nature suggest a strong association with the loss 
of Treg function in Gimap5sph/sph over time and link the loss of full-length Foxo expression in 
Gimap5sph/sph lymphocytes with the onset of lymphopenia, impaired lymphocyte proliferation 
and increased effector function and differentiation into Th17 cells (Figure 1). The detailed 
mechanistic insight into the loss of immunological tolerance occurring in Gimap5sph/sph mice 
may ultimately provide important leads as to how polyadenylation polymorphisms in 
GIMAP5 predispose human patients to T1D or SLE.  
5. Mutations in hematopietic protein 1; an immunodeficiency resulting in 
loss of a broad range of immunological functions 
Genetic aberrancies causing severe combined immunodeficiency (SCID) are generally rare 
and associated with a high morbidity and/or mortality. They often present significant 
challenges in terms of treatment due to the wide variety of immune cells that can be 
affected. Therefore, besides defining the genetic footprint underlying SCID, a critical 
challenge lies in obtaining a thorough understanding of the degree of the immunodeficiency 
presented by specific mutations in genes, including defining the types of immune cells 
affected and functional aberrancies observed. Our laboratory previously identified a 
germline mutant, designated Lampe2, which exhibited impaired NK as well as CD8+ T cell 
cytoloytic effector function as determined by the in vivo cytotoxicity assay described above 
(Figure 2a). The G1 pedigrees of these germline mutants were selected to establish a 
homozygote colony used for genetic analysis and further phenotypic characterization. The 
mutation behaved as strictly recessive, in that normal cytolytic effector functions were 
observed in heterozygote mutant mice. Further characterization of 6-week-old homozygote 
Lampe2 mutants revealed markedly reduced numbers of CD8+ T, CD4+ T and B cell 
populations, and a slight reduction in NK cells (Figure 2b). In contrast, an increase in the 
number of macrophages in the spleen was observed (Figure 2b). Notably, upon necropsy, 
the liver exhibited white patches at the periphery (Figure 2c) which upon histological 
analysis revealed large areas of necrosis and significant hematopoietic infiltrate and 
inflammation (Figure 2d-e).  
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Figure 2. Impaired NK and CD8+ T cell function and development of liver injury in Lampe2 mice. (a) 
Reduced clearance of CFSE labeled β-2m-deficient and antigen-specific target splenocytes in Lampe 2 
germline mutants compared to C57BL/6J control mice in vivo. 48 hours after transfer, blood samples 
were collected and analyzed for the presence of wildtype splenocytes (low-CFSE) and Kb-deficient 
splenocytes (medium-CFSE). The percentage killing is calculated from the ratio between β-2m-deficient 
and C57BL/6J cells administered to β2m-deficient and control naïve C57BL/6J recipients. (b) The 
percentage of NK cells, macrophages, CD8+ T cells, CD4+ T cells and B cells in C57BL/6J and 
homozygote Lampe2 mutant mice. (n > 3) (c) Macroscopic and histological analysis of Lampe2 livers.*= 
P<0.05; **= P<0.01; ***= P<0.001 
To identify the causative mutation in Lampe2 mice, we performed coarse mapping by 
crossing Lampe2 C57BL/6J homozygotes males with 129S1/SvImJ females. The resulting F1 
offspring were intercrossed to generate a F2 and a total of 24 offspring (6 Lampe2 mutant- 
and 18 wildtype-phenotypes) were analyzed for both phenotype and genotype. Genotyping 
was performed using a genome wide custom-made 353-SNP map distinguishing C57BL/6J 
and 129S1/SvImJ genetic backgrounds. Coarse mapping revealed a single peak with a LOD 
score of ~5.86 for SNP rs13482738 located on the distal end of chromosome 15 (Figure 3A).  
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Figure 3. Coarse mapping and identification of the causative mutation in Lampe2 mice. (a) Low-
resolution mapping of the Lampe2 mutation based on twenty-four mice and a panel of 353 SNPs 
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covering the entire genome. The Lampe2 phenotype was linked to the distal site of chromosome 15. (b,c), 
the A→G intronic mutation causes a new acceptor splice site (b) resulting in the inclusion of 7 
nucleotides intronic sequence into mature Hem1 transcript as determined by sequencing of Hem1 cDNA 
(c). (d) At the protein level, the mutation is predicted to cause a frameshift at amino acid 261 with 
alternative coding and premature stop at amino acid 318, resulting in a largely truncated Hem1 protein.  
The critical region was defined by proximal marker rs6285067 (at position 95.14 Mb) and the 
distal end of chromosome 15 (at 103.40 Mb) and consisted of ~8.26 Mb genomic DNA 
containing 242 annotated genes. Among the annotated genes, Hematopoietic protein 1 (Hem-1 
aka NCK associated protein 1 like or Nckap1l) presented a clear candidate gene, in that a 
previously reported ENU germline mutant carrying a point mutation (referred to as the 
NBT.1 mutation) causing a premature stop and absence of protein expression, exhibits 
striking similar phenotypes compared to Lampe2 mice. Specifically, these mice exhibit 
lymphopenia with a reduced number of peripheral CD4+ T, CD8+ T and B cells, and on the 
other hand showed marked expansion of myeloid cells, including neutrophils and 
macrophages. Moreover, the liver phenotype in mice carrying the NBT.1 mutation bears 
high resemblance with the liver phenotype observed in Lampe2 mice—i.e. the occurrence of 
whitish liver margins and large areas of inflammation. Hem1 is a member of the Hem family 
of cytoplasmic adaptor molecules predominantly and is expressed exclusively in 
hematopoietic cells, including T and B cells, macrophages, DCs and granulocytes. Hem1 
plays a critical role in the reorganization of actin cytoskeleton and as such, affects a wide 
variety of immune functions, including chemotaxis/migration, adhesion, formation of an 
immune synapse and phagocytosis. Sequencing of Hem1 exons, including 50 bps of 
proximal/distal intronic sequence, was performed by Sanger sequencing methodology using 
genomic DNA and revealed a single A→G point mutation in intron 8-9 located 6 nucleotides 
upstream of the exon 9 acceptor splice site (Figure 3b). The A→G intronic nucleotide change 
potentially presented a new acceptor splice site and indeed sequencing of Hem-1 mRNA 
isolated from spleen showed the inclusion of 7 intronic nucleotides in mRNA derived from 
Lampe2 mice (Figure 3c). At the protein level, the inclusion of intronic nucleotides is 
predicted to result in a frame-shift and alternative coding following residue 261, and a 
premature stop at amino acid 381 resulting in a largely truncated Hem-1 protein in Lampe2 
mice (Figure 3d). Given the similarities of the Lampe2 and NBT.1 mutant phenotypes and the 
predicted severe impact of the Lampe2 mutation on Hem-1 protein expression, we concluded 
that the mutation in Hem-1 caused the observed phenotypes in Lampe2 mice (hereafter 
referred to as Hem1lampe2).  
Hem1 is part of the Wiskott-Aldrich syndrome protein family Verprolin-homologous 
protein (WAVE) protein complex in hematopoietic cells regulating cell mobility and 
intracellular processes requiring rearrangement of the cytoskeleton following immuno-
receptor activation, including B and T cell, chemokine and innate immune receptors such 
as Toll-like receptors. Specifically, receptor triggering causes activation of Rho family of 
Guanosine triphosphatases (GTPases) such as CDC42, RhoA and Rac ultimately resulting 
in the activation of downstream adaptor complexes involved in the regulating of actin 
(de)polymerization. For hematopoietic cells, the adaptor complexes Wiskott-Aldrich 
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syndrome protein (WASP) and WAVE are particularly important for the control of actin 
polymerization45-48. The hematopoietic cell-specific WAVE complex consists of a 
pentameric subunit complex including, Sra-1 (Specifically Rac-associated protein-1), 
Hem1, Abi (Abelson interactor 1 or 2), WAVE, and HSPC300 (Hematopoietic 
stem/progenitor cell protein 300)49. Under non-stimulated conditions, the WAVE 
complex is inactive, but following immunoreceptor activation, GTP-bound Rac binds the 
pentameric complex presumably through Sra149. In addition, this complex requires 
binding of phophatidylinositol (3,4,5) triphosphate (PIP3) interaction and 
phosphorylation by kinases50, including Abl kinase and Mitogen-activated protein 
kinases51. Ultimately, this results in a conformational change revealing the WAVE-
specific VCA (Verprolin-homology, Cofillin-homology, and acidic) region and allow 
interaction with the actin-regulatory complex (Arp2/3), ultimately converting monomeric 
actin (G-actin) into filamentous actin (F-actin). Interestingly, the absence of individual 
subunit components often causes the degradation of all components of the WAVE 
complex resulting in aberrant actin polymerization. The consequences of deregulated 
actin polymerization in hematopoietic cells are wide-ranging and affect broad 
immunological functions, including but not limited to: 1) leukocyte 
migration/chemotaxis, 2) loss of immune synapse formation affecting T and B cell 
receptor signaling (thereby affecting T cell function and development), 3) leukocyte 
adhesion, and 4) DC-specific phagocytosis and their ability to cross present/prime T 
cells. As such, mutations in the specific subunit components of the WAVE complex 
resulting in abnormal gene expression/function cause severe combined 
immunodeficiencies that stretch beyond lymphocyte populations also affecting 
granulocyte function and are predicted to correlate with high mortality/morbidity. 
6. Implications for human PID 
Assessing the immune system using ENU mutagenesis in mice has previously led to 
important breakthrough discoveries in understanding the genetics in human patients with 
PID. A prime example is the identification of the 3d allele—a missense allele of Unc93b1, a 
gene encoding an ER membrane protein with 12 membrane spanning motifs with a 
previously unknown function. 3d germline mutants were identified in a screen probing 
the response of macrophages derived from ENU germline mice to a variety of TLR-
ligands. Homozygote 3d mutant mice were found to be unresponsive to ligands activating 
endosomal TLRs, but exhibited normal responses to TLRs expressed at the surface39. 
Interestingly, at the same time Casrouge et al. identified two unrelated human patients 
that presented recurrent infections with Herpes simplex virus-1 (HSV-1) resulting in 
encephalitis (HSE) and showed remarkable similarities between the phenotypes observed 
in the human patients and in 3d mutant mice. Specifically, both patients were 
unresponsive to endosomal TLR stimulation and showed a high viral susceptibility. 
Following the identification of the causative mutation in 3d mice as being a missense 
allele of Unc93b1, subsequent sequencing of the human patients indeed revealed aberrant 
mutations in UNC93B52. This example highlights the power of ENU mutagenesis and its 
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unbiased approach, by uncovering the function of genes for which a biological function is 
otherwise difficult to predict.  
With regard to the Gimap5 and Hem-1 germline mutations described in this chapter, both 
present examples of genetic mutations leading to severe combined immunodeficiencies. 
Although limited information is available with regard to genetic mutations causing a null 
phenotype in human GIMAP5 or HEM1, ample evidence exist that dysregulation of these 
genes plays an important role in human disease. A previous report suggests that SLE 
patients were shown to have a trend for lower GIMAP5 mRNA expression in peripheral 
blood mononuclear cells compared to healthy controls16. Moreover, a poly-adenylation 
mutation in the 3’ region of GIMAP5, resulting in minor changes in GIMAP5 mRNA 
expression in peripheral blood mononuclear cells, are associated with increased 
predisposition to SLE and T1D15, 16, 53. Thus far, the effect on GIMAP protein expression, 
specifically in lymphocytes of homozygote/heterozygote carriers for this mutation, remains 
elusive and warrants further research. Our studies using Gimap5-deficient mice point to an 
important role for Gimap5 in maintaining peripheral immunological tolerance that is 
intrinsically related to the loss of Gimap5 expression in CD4+ T cells. Thus, research efforts 
may be directed to a better understanding of GIMAP5 and FOXO protein expression 
specifically in CD4+ T cells in human patients with SLE or T1D that carry the 
polyadenylation mutation in GIMAP5.  
Finally, perhaps due to its indispensable role in a wide variety of immune pathways, 
mutations in human HEM1 leading to dysregulated actin polymerization, have thus far not 
been reported. Nonetheless, over- or under-expression of HEM1 is associated with disease 
prognosis in leukemia54. Specifically, HEM1 overexpression in B-cell chronic lymphocytic 
leukemia (CLL) is associated with a poor outcome, whereas down-regulation of HEM1 
expression in CLL cells rendered tumor cells more susceptible to fludarabine-mediated 
killing54. These findings may indicate the critical role for HEM1 in invasion and/or 
metastasis of tumor cells from hematopoietic origin.  
7. Concluding remarks 
A major challenge in the field of genomics is to obtain a comprehensive understanding of 
the functions of all annotated mammalian genes. Whereas identification and analysis of 
genome wide SNPs and/or unique nucleotide changes are drastically improved following 
the development of next generation sequencing technologies, understanding the 
consequences of such genetic variants remains a major challenge in virtually all 
biomedical fields. ENU mutagenesis provides one approach that is both powerful and 
unbiased, uncovering gene function by introducing the sort of genetic abnormalities that 
can be observed in human patients (e.g. primary immuno-deficiencies). Ultimately, 
utilization of both forward and reverse genetic approaches will be instrumental in closing 
the existing phenotype gap and will help us understand the association between 
identified genetic variants, the implications for protein and biological function, and 
human disease.  
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